DDD

DOUBLE BOND PHARMACEUTICAL INT. AB SER. B

No trades
See on Supercharts
Market capitalization
‪61.42 M‬SEK
‪−17.34 M‬SEK
‪1.37 M‬SEK
Beta (1Y)
0.95

About DOUBLE BOND PHARMACEUTICAL INT. AB SER. B

CEO
Igor Lokot
Headquarters
Uppsala
Founded
2014
ISIN
SE0007185525
FIGI
BBG009DFBCW8
Double Bond Pharmaceutical International AB is a pharmaceutical company, which engages in developing and commercializing approaches for treatment of cancers, infections, autoimmune diseases, and life-threatening disorders. It also involves in designing medicinal products for patients suffering from diseases such as cancer, inflammation, asthma or diabetes. The company was founded on November 21, 2014 and is headquartered in Uppsala, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of DBP.B is 0.560 SEK — it has decreased by 6.98% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NGM exchange DOUBLE BOND PHARMACEUTICAL INT. AB SER. B stocks are traded under the ticker DBP.B.
DBP.B stock is 7.50% volatile and has beta coefficient of 0.95. Check out the list of the most volatile stocks — is DOUBLE BOND PHARMACEUTICAL INT. AB SER. B there?
Yes, you can track DOUBLE BOND PHARMACEUTICAL INT. AB SER. B financials in yearly and quarterly reports right on TradingView.
DBP.B stock has fallen by 18.84% compared to the previous week, the month change is a 9.97% fall, over the last year DOUBLE BOND PHARMACEUTICAL INT. AB SER. B has showed a 29.11% decrease.
DBP.B net income for the last quarter is ‪−7.09 M‬ SEK, while the quarter before that showed ‪−3.75 M‬ SEK of net income which accounts for −88.87% change. Track more DOUBLE BOND PHARMACEUTICAL INT. AB SER. B financial stats to get the full picture.
Today DOUBLE BOND PHARMACEUTICAL INT. AB SER. B has the market capitalization of ‪61.42 M‬, it has decreased by 0.53% over the last week.
No, DBP.B doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DBP.B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DOUBLE BOND PHARMACEUTICAL INT. AB SER. B stock right from TradingView charts — choose your broker and connect to your account.
DBP.B reached its all-time high on Nov 6, 2018 with the price of 19.400 SEK, and its all-time low was 0.252 SEK and was reached on Aug 21, 2023.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DOUBLE BOND PHARMACEUTICAL INT. AB SER. B technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DOUBLE BOND PHARMACEUTICAL INT. AB SER. B stock shows the sell signal. See more of DOUBLE BOND PHARMACEUTICAL INT. AB SER. B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.